NovoCure Limited Stock News

NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Novocure announced encouraging results from a phase 3 study of its TTFields therapy in treating brain metastases. The therapy previously failed to reach a primary endpoint in a separate study for trea

Novocure announced results from a phase 3 study of its TTFields therapy in treating brain metastases. Patients treated with TTFields experienced a significant improvement in the median time to intracr

NovoCure (NVCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d

Novocure (NASDAQ:NVCR) shares soared on Wednesday as the oncology firm revealed its investigational medical device slowed the spread of cancer to the brain in patients with lung cancer during a late-

The mean of analysts' price targets for NovoCure (NVCR) points to a 63.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst

NovoCure (NVCR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.36 per share a year ago.

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street loves a good comeback story. It's why analysts often put elevated price targets on severely beaten-down stocks.

Novocure (NASDAQ: NVCR ) layoffs are in the news after the company announced that it will be cutting 13% of its workers in a restructuring effort. Those layoffs will see the oncology company reducing

NovoCure is an oncology company that offers a novel therapy for solid tumors called TTFields and comprehensive patient support services. Despite a challenging year, NovoCure's core business is healthy

Novocure has a novel and original way to treat cancer. However, the company's financial results haven't been great.

The cancer treatment device developer released its latest set of quarterly results. These were a mixed bag, as it notched a beat on earnings but missed on revenue.

NovoCure doesn't have any direct competitors for its anti-cancer device. The product could see its indications expanded into various other niches.

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA app